



1645
#13

PATENT
ATTORNEY DOCKET NO. 01948/074002

Certificate of Mailing: Date of Deposit: October 30, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Moya Kinnealey
Printed name of person mailing correspondence

Moya Kinnealey
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark A. Exley et al.	Art Unit:	1645
Serial No.:	09/885,768	Examiner:	Not Yet Assigned
Filed:	June 19, 2001	Customer No.:	21559
Title:	Compositions and Methods of Monoclonal and Polyclonal Antibodies Specific for T Cell Subpopulations		

Assistant Commissioner For Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

Please apply any charges or credits to Deposit Account 03-2095.

Respectfully submitted,

Date: October 30, 2002

Kristina Bleker-Brady
Kristina Bleker-Brady, Ph.D.
Reg. No. 39,109

RECEIVED
NOV 07 2002
TECH CENTER 1600/2900

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

W:\PTO Forms New for 2001\Information Disclosure Statement.wpd



21559

PATENT TRADEMARK OFFICE

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	01948/074002
		Serial No.	09/885,768
		Applicant	Mark A. Exley et al.
		Filing Date	June 19, 2001
		Group	1645
		Customer No.	21559
		IDS Filed	October 30, 2002

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 677 533 A	18 Oct. 1995	EPO			No
	EP 1 025 854 A	9 August 2000	EPO			Yes (abstract)
	WO 99/34209	8 July 1999	WIPO			No

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Exley et al., "CD161 (NKR-P1A) Costimulation of CD1d-dependent Activation of Human T Cells Expressing Invariant Vα24JαQ T Cell Receptor α Chains," <i>J. Exp. Med.</i> 188(5):867-876 (1998).
	Nicol et al., "Human Invariant Vα24* Natural Killer T Cells Activated By α-galactosylceramide (KRN7000) Have Cytotoxic Anti-tumour Activity Through Mechanisms Distinct From T Cells And Natural Killer Cells," <i>Immunology</i> 99:229-234 (2000).
	Wilson et al., "Development of Monoclonal Antibodies to Vα24JαQ T Cells Detects Alterations In Cell Frequency In New-Onset Type 1 Diabetes Patients," <i>Diabetes</i> vol. 50, Supplement 2 (2001).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED
NOV 07 2002
TECH CENTER 1600/2900